LEESOL (Co-CEOs Seungwoo Lee and Gusung Kwon), a mental healthcare startup with its own brainwave synchronization technology, announced on the 19th that it has secured a Series A2 bridge round investment totaling 3 billion won.
BNK Venture Investment participated as the lead investor in this round, with follow-on investments from Spacetime Investment, Suinvestment Capital, and Vine Ventures. This brings Risol's cumulative investment to over 7.6 billion won.
This investment is a bridge round following a KRW 4 billion Series A funding round in 2024. The investment is based on Lysol's capabilities in electronic medicine (digital therapeutic technology) and personalized healthcare services, as well as its business performance and potential for global expansion.
Lysol provides solutions for mental and nervous system disorders, such as sleep disorders, depression, stress, dementia prevention, and chronic pain management, through electronic pharmaceutical technology that combines microcurrent-based brainwave synchronization technology and AI biosignal analysis algorithms.
Their flagship product, the "Sleepisol" series of wearable devices, utilizes technology that induces brainwave synchronization deep within the brain, helping to improve sleep quality and mental stability. The technology was clinically tested at Seoul National University Bundang Hospital and published in an SCI-level international journal. Cumulative sales have surpassed 50,000 units in Korea, the United States, and Japan.
Lysol achieved sales of approximately 2.6 billion won in 2025 and aims to achieve over 6 billion won in 2026. It entered the Japanese market through collaboration with Japan's Funai Research Institute, and plans to fully expand into the US market starting in 2027.
"SleepySol Bio," a sleep and mental health management app based on Samsung Electronics' Samsung Health SDK, has surpassed 1.7 million cumulative global downloads. It was selected as the "2025 Google Play Global Watch App of the Year" in 10 countries: the US, India, Indonesia, Australia, Brazil, Mexico, the UK, Germany, and Canada. Since its selection, the app has seen increased user traffic, particularly in the US, Europe, and Japan. Starting in 2026, it plans to introduce a subscription model based on sleep and cognitive analysis reports.
Risol has won the CES 2025 Innovation Award (SleepySol Light), was selected as the '2025 Baby Unicorn' by the Ministry of SMEs and Startups, the NextRise 2025 Innovation Award, and the 2025 Prime Minister's Award for Contribution to Venture and Startup Promotion.
The company plans to use this investment to advance digital therapeutics and electronic medicine technologies, develop new wellness and therapeutic devices, expand personalized healthcare services globally, obtain global certifications and enter overseas markets, and enhance its AI-based mental health platform.
Kwon Koo-seong, Co-CEO of Risol, stated that this investment reaffirmed the company's technological prowess, commercialization success, and global growth potential. He also explained that the company has partnered with Hyundai Engineering & Construction to apply its products to the Hillstate Lake Songdo 4th development and is preparing to launch a new product, "DAYZER."
- See more related articles
You must be logged in to post a comment.